Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06839391

Effect of Hyaluronidase in Different Doses Added to Bupivacaine on TAB Block Quality During CS

evaluate the efficacy of hyaluronidase in different doses as an adjuvant to bupivacaine in ultrasound-guided TAB block during CS

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Age range

20 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Early Phase 1

About this study

Hyaluronidase acts by catalyzing the hydrolysis of hyaluronan, decreased its viscosity, and enchasing the tissue permeability. So, this makes it a suitable additive for other drugs to speed up their distribution and delivery especially in ophthalmic surgery. Several studies showed that multiple injection techniques of TAB block were more successful with a faster onset of anesthesia and higher success rates, with a change in the incidence of complications.

This double-blinded randomized prospective study was conducted to evaluate the efficacy of hyaluronidase in different doses as an adjuvant to bupivacaine in ultrasound-guided TAB block during CS . The primary outcome of this study was the duration of sensory block, while secondary outcomes included the onset of sensory block, success rate, total doses of intraoperative rescue analgesia, number of patients needed for postoperative rescue analgesia, and complications.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • pregnant 20-45 y medical free

Exclusion criteria

  • • Hepatic.
  • Renal.
  • Diabetic.
  • Hypertensive.
  • Cardiovascular dysfunction.

Treatment and study plan

Hyaluronidase

Drug

Effect of hyaluronidases in different doses added to bupivacaine on quality of ultrasound-guided TAB block during CS ,

Primary outcomes

  1. visual analogue scale

    Time frame: 2-6-10-16-24 hours postoperatively

    postoperatively pain assesment

Sponsors and collaborators

Lead sponsor

Benha University

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Feb 21, 2025
Registry last updated
Feb 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.